Drug Profile

Research programme: antibodies - Abilita Therapeutics/Abveris

Latest Information Update: 07 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abilita Bio; Abveris
Developer Abilita Therapeutics; Abveris
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action G protein-coupled receptor modulators; Immunomodulators; Membrane protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

01 Jun 2023 Abilita Bio is now called Abilita Therapeutics
01 Jun 2023 Antibodies is available for licensing as of 01 Jun 2023. https://www.abilitabio.com/
21 Feb 2023 Preclinical trials in Cancer in USA (Parenteral) before February 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com